Table 2.
Reported treatment coverage
|
Annual community-wide treatment arm |
Biannual community-wide treatment arm |
|||||||
|---|---|---|---|---|---|---|---|---|
| Round 1 | Round 3 | Round 1 | Round 2 | Round 3 | Round 4 | |||
| Households reporting community health volunteer visit | 2074 (90·8%) | 2375 (95·2%) | 2074 (91·4%) | 2174 (88·3%) | 2330 (95·3%) | 2112 (92·6%) | ||
| Eligible individuals interviewed | 12 102 | 12 227 | 11 453 | 11 276 | 11 908 | 11 122 | ||
| Eligible population treatment coverage | 9765 (80·7%) | 10 140 (82·9%) | 9220 (80·5%) | 8701 (77·2%) | 9882 (83·0%) | 8231 (74·0%) | ||
| Treatment coverage by age group | ||||||||
| Pre-school-aged children (2–4 years) | ||||||||
| Treated (total) | 83·1% (80·2–86·0) | 77·8 (74·3–81·2) | 84·0% (81·3–86·6) | 77·3% (72·7–81·8) | 79·2% (76·4–82·1) | 73·8% (69·5–78·0) | ||
| In school | 15·1% (12·9–17·3) | 14·5% (12·0–16·9) | 15·6% (12·9–18·2) | .. | 14·5% (12·1–17·0) | .. | ||
| At home | 68·0% (64·9–72·8) | 62·7% (58·8–66·6) | 68·4% (65·4–73·5) | .. | 64·6% (61·6–67·6) | .. | ||
| School-aged children (5–14 years) | ||||||||
| Treated (total) | 91·0% (88·9–93·1) | 89·5% (87·1–91·8) | 90·5% (88·5–92·4) | 81·8% (78·5–85·0) | 89·6% (87·2–91·9) | 79·9% (76·8–83·0) | ||
| In school | 68·8% (65·8–71·8) | 66·5% (63·3–69·7) | 65·8% (62·4–69·2) | .. | 64·8% (60·2–69·4) | .. | ||
| At home | 25·1% (22·2–28·1) | 21·4% (18·6–84·2) | 24·7% (23·8–31·0) | .. | 23·8% (20·3–27·3) | .. | ||
| Adults (≥15 years) | ||||||||
| Treated (total) | 73·7% (72·0–75·4) | 79·7% (78·4–81·1) | 74·2% (72·3–76·0) | 74·5% (71·6–77·3) | 79·6% (78·1–81·2) | 70·4% (67·7–73·0) | ||
| In school | 10·8% (9·8–11·8) | 7·7% (6·9–8·6) | 9·3% (8·4–10·2) | .. | 7·7% (6·8–8·5) | .. | ||
| At home | 63·0% (61·3–65·5) | 71·7% (70·0–73·4) | 64·9% (63·2–67·3) | .. | 71·5% (70·0–73·1) | .. | ||
| Adolescent girls (10–19 years) | ||||||||
| Treated (total) | 81·1% (78·5–83·7) | 84·4% (82·0–86·7) | 81·7% (79·2–84·3) | 79·0% (75·9–82·0) | 85·1% (82·7–87·4) | 78·0% (74·6–81·4) | ||
| In school | 59·6% (56·0–63·1) | 55·2% (52·0–58·4) | 57·0% (53·5–60·5) | .. | 55·8% (51·3–60·4) | .. | ||
| At home | 21·51% (20·7–26·5) | 27·9% (24·8–31·1) | 27·1% (24·0–30·2) | .. | 28·5% (25·4–31·7) | .. | ||
| Women of reproductive age (15–49 years) | ||||||||
| Treated (total) | 73·7% (71·7–75·7) | 81·6% (80·0–83·2) | 74·1% (71·8–76·4) | 75·1% (72·3–77·9) | 80·4% (78·6–82·2) | 73·1% (70·1–76·1) | ||
| In school | 11·3% (9·8–12·9) | 8·0% (7·0–9·0) | 9·7% (8·5–10·9) | .. | 8·0% (6·8–9·1) | .. | ||
| At home | 62·4% (60·3–65·2) | 73·2% (71·2–75·2) | 64·4% (62·8–67·0) | .. | 72·1% (70·4–73·7) | .. | ||
Coverage data are stratified by trial target populations (pre-school-aged children, school-aged children, and adults) and additional WHO-defined target groups (adolescent girls and women of reproductive age).